Four years ago, Pfizer spent $56 million to bag Icagen and add its ion channel R&D platform and pipeline in North Carolina with its pain drug development arm in the U.K. But yesterday the pharma giant spun the platform back out to a small contract research group in Cambridge, MA, called XRPro Sciences, which will now combine its operations into an expanded research services operation that will cater to the biopharma industry.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Stop-smoking apps aren't new, but Pfizer and the American Lung Association's latest enlists friends and family--and their pocketbooks, too. The Quitter's Circle lets smokers invite friends to their quit teams and includes educational support, healthcare provider support and even the ability to crowdsource funds to finance the effort.
We checked and everything is done correctly on our tax obligations, 9 drug companies said in separate submissions ahead of testimony on July 1 to an Australian Senate inquiry on tax avoidance.
The CDC's Advisory Committee for Immunization Practices gave the go-ahead for wider use of meningitis B vaccines, but stopped short of a universal recommendation, not the result many--including GlaxoSmithKline and Pfizer--were hoping to see.
The mayor of London has come up with a scheme to bridge the financial chasm between the U.K. and U.S. biotech hubs. Officials have called Eli Lilly, Pfizer and JP Morgan to a meeting to discuss the plan, which entails creating a £10 billion ($15 billion) fund to invest in drugs across the development spectrum, The Financial Times reports.
The CDC's Advisory Committee on Immunization Practices (ACIP) voted on Wednesday to expand its recommendation for meningitis B vaccines, but it wasn't the broad recommendation that many were hoping to see.
After dealing with two preapproval inspections and two dozen FDA observations, injectables specialist Hospira says it has gotten FDA approval and is ramping up production at its new plant in India.
The game is on at Hospira's massive new manufacturing plant in India. After two delays to work out kinks identified by the FDA, the drugmaker says the agency has signed off on it and Hospira has started "limited commercial production at the facility."
Growth in emerging markets may be slowing, but pharma sales there are still outpacing those everywhere else. And if recent numbers are any indication, AstraZeneca is topping its rivals for emerging markets expansion.